Related Experiment Video

Updated: Jun 21, 2025

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.8K

Deciphering Disease Profiles in the Era of Prostate-Specific Membrane Antigen Positron Emission Tomography:

Peter D Zang1, Salvador Jaime-Casas2, Wesley Yip2

  • 1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA.

JCO Precision Oncology
|July 16, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

152
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

12.1K

Related Experiment Videos

Last Updated: Jun 21, 2025

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

152
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

12.1K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.1K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.1K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

105
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
105
Proteomics01:33

Proteomics

7.3K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.3K

Articles linked to this work by shared authors, journal, and citation graph.

Evaluating Global Disparities in the Availability of Prostate Cancer Clinical Trials.

JCO global oncology·2026

Assessing Geographic Disparities in the Availability of Renal Cell Carcinoma Clinical Trials in the United States.

JCO oncology practice·2026

Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors.

Cancer research communications·2026

Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability.

Cancers·2026

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration.

JCO precision oncology·2026

Disparities in Outcomes in Latino Subpopulations with Localized Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Analysis.

Cancers·2026

Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity With High-Density Progenitor Cell Regions Correlating With High-Risk Disease.

JCO precision oncology·2026

Genomic Landscape and Clinical Actionability of Skin Adnexal Carcinomas.

JCO precision oncology·2026

Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab.

JCO precision oncology·2026

Genomic Analysis Using Liquid Biopsy: Considerations for Pretest Counseling in UK Practice.

JCO precision oncology·2026

Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2026

Tailoring Escalated Adjuvant Chemotherapy for Multifocal and Multicentric Breast Cancer With Low Tumor Burden.

JCO precision oncology·2026

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy by Age After PCI: A SHARE Substudy.

JACC. Asia·2026

Does Prior Androgen Exposure Alter Outcomes After Gynecomastia Surgery? A Propensity-Matched Analysis.

The American surgeon·2026

Risk-adapted MRI Protocols for the Detection of Clinically Significant Prostate Cancer.

Radiology. Imaging cancer·2026

Multimodal Transformer Integrating CT and Pathology for Postoperative Risk Stratification in Stage I Non-Small Cell Lung Cancer.

Radiology. Imaging cancer·2026

Evaluation of programmed death ligand 1 (PD-L1) expression and CD8+ T-cell immune response in primary pterygium.

Indian journal of ophthalmology·2026

Severity at the Gates: Or Why Prevention is the Aim of Reproductive Genetic Carrier Screening.

The American journal of bioethics : AJOB·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us